SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Northfield Lab(NFLD)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Todd N. Weisrock who wrote (82)8/21/1998 12:27:00 PM
From: Dixie7777  Read Replies (1) of 148
 
For those of you that have been interested in the biotech field and especially
emerging opportunities, you may wish to review the following. Obviously your
own DD will always be the only measure of a worthy investment.

With that said, there are many of us that would like to introduce you to
Sanguine. Very possibly the best kept secret in its field. It is the only product of
its kind with a history of live trials that proved its efficacy. (You must read the
thread for the research and conduct your own DD.) All other candidates to date
have either fallen away with too high a mortality rate, or have severe limitations
that will probably inhibit their marketability. Sanguine has had ZERO mortality
rate in its live trials.

We also believe that this "secret" is about to emerge into the mainstream with
recognition by a major investment banking firm and a potential major
pharmaceutical suitor.

Started By: Profiteer
Date: May 20 1998 6:28PM ET

SANGUINE CORP. (SGNC)
Due to the overwhelming renewed interest in (SGNC), this thread should be helpful as a
forum for Information & Discussion.

SANGUINE CORP. (SGNC) a California corporation is engaged in the development
of a synthetic red blood cell product called "PHER-02." Management believes the
PHER-02 has advantages over human blood:
ú It can be sterilized to be free of disease including (HIV.)
ú is believed to have the quality of a universal match for all blood types:
ú can be mass-produced.
ú may be stored much longer than human blood. Sanguine estimates the annual market
potential for this product at $20 billion.

Dr. Thomas C. Drees: Company President & Chief Executive Officer

The most recent post at the time of copying this info is,
Message 5075776
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News